238 related articles for article (PubMed ID: 32162819)
21. Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors.
Watanabe H; Fujishima F; Komoto I; Imamura M; Hijioka S; Hara K; Yatabe Y; Kudo A; Masui T; Tsuchikawa T; Sakamoto K; Shiga H; Nakamura T; Nakaya N; Motoi F; Unno M; Sasano H
Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159042
[TBL] [Abstract][Full Text] [Related]
22. Somatostatin Analogs Treated Small Intestinal Neuroendocrine Tumor Patients Circulating MicroRNAs.
Li SC; Khan M; Caplin M; Meyer T; Öberg K; Giandomenico V
PLoS One; 2015; 10(5):e0125553. PubMed ID: 25942502
[TBL] [Abstract][Full Text] [Related]
23. Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
Carmona-Bayonas A; Jiménez-Fonseca P; Custodio A; Grande E; Capdevila J; López C; Teule A; Garcia-Carbonero R;
Curr Oncol Rep; 2017 Sep; 19(11):72. PubMed ID: 28920153
[TBL] [Abstract][Full Text] [Related]
24. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
[TBL] [Abstract][Full Text] [Related]
25. Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs.
Prinzi N; Raimondi A; Maccauro M; Milione M; Garanzini E; Torchio M; Corti F; Nichetti F; Lo Russo G; Giacomelli L; Mazzaferro V; Di Bartolomeo M; Seregni E; de Braud F; Pusceddu S
Future Oncol; 2019 Sep; 15(26):3015-3024. PubMed ID: 31424273
[No Abstract] [Full Text] [Related]
26. Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life.
Faggiano A; Carratù AC; Guadagno E; Tafuto S; Tatangelo F; Riccardi F; Mocerino C; Palmieri G; Damiano V; Siciliano R; Leo S; Mauro A; Tozzi LF; Battista C; De Rosa G; Colao A
Oncotarget; 2016 Feb; 7(5):5538-47. PubMed ID: 26701729
[TBL] [Abstract][Full Text] [Related]
27. A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on
Gålne A; Almquist H; Almquist M; Hindorf C; Ohlsson T; Nordenström E; Sundlöv A; Trägårdh E
J Nucl Med; 2019 Dec; 60(12):1717-1723. PubMed ID: 31000584
[TBL] [Abstract][Full Text] [Related]
28. Occurrence of exocrine pancreatic insufficiency in patients with advanced neuroendocrine tumors treated with somatostatin analogs.
Rinzivillo M; De Felice I; Magi L; Annibale B; Panzuto F
Pancreatology; 2020 Jul; 20(5):875-879. PubMed ID: 32684368
[TBL] [Abstract][Full Text] [Related]
29. Management of Ileal Neuroendocrine Tumors with Liver Metastases.
Fisher AT; Titan AL; Foster DS; Worth PJ; Poultsides GA; Visser BC; Dua MM; Norton JA
J Gastrointest Surg; 2020 Jul; 24(7):1530-1539. PubMed ID: 31346887
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study.
Ida H; Honma Y; Hirano H; Shoji H; Iwasa S; Okita N; Takashima A; Kato K; Fukuda T; Boku N
Invest New Drugs; 2019 Jun; 37(3):573-578. PubMed ID: 30267338
[TBL] [Abstract][Full Text] [Related]
31. Budget Impact of Somatostatin Analogs (SSAs) as Treatment for Metastatic Gastroenteropancreatic Neuroendocrine Tumors (mGEP-NETs) in US Hospitals.
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):10-1. PubMed ID: 27168105
[No Abstract] [Full Text] [Related]
32. Chronic Use of Long-Acting Somatostatin Analogues (SSAs) and Exocrine Pancreatic Insufficiency (EPI) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Under-recognized Adverse Effect.
Saif MW; Romano A; Smith MH; Patel R; Relias V
Cancer Med J; 2020; 3(2):75-84. PubMed ID: 32405630
[TBL] [Abstract][Full Text] [Related]
33. Systemic treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETS): current approaches and future options.
Strosberg JR
Endocr Pract; 2014 Feb; 20(2):167-75. PubMed ID: 24014009
[TBL] [Abstract][Full Text] [Related]
34. [Antiproliferative Effect of Somatostatin Analogs - Data Analyses and Clinical Applications in the Context of the CLARINET Study].
Bencsiková B
Klin Onkol; 2016; 29(4):253-8. PubMed ID: 27534781
[TBL] [Abstract][Full Text] [Related]
35. Prophylactic cholecystectomy in midgut carcinoid patients.
Norlén O; Hessman O; Stålberg P; Akerström G; Hellman P
World J Surg; 2010 Jun; 34(6):1361-7. PubMed ID: 20130865
[TBL] [Abstract][Full Text] [Related]
36. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
Cives M; Strosberg J
Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185
[TBL] [Abstract][Full Text] [Related]
37. Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study.
Lesén E; Björstad Å; Björholt I; Marlow T; Bollano E; Feuilly M; Marteau F; Welin S; Elf AK; Johanson V
Scand J Gastroenterol; 2018 Dec; 53(12):1509-1518. PubMed ID: 30449217
[TBL] [Abstract][Full Text] [Related]
38. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
[TBL] [Abstract][Full Text] [Related]
39. Radioguided surgery with radiolabeled somatostatin analogs: not only in GEP-NETs.
Cuccurullo V; Di Stasio GD; Mansi L
Nucl Med Rev Cent East Eur; 2017; 20(1):49-56. PubMed ID: 28218348
[TBL] [Abstract][Full Text] [Related]
40. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.
Herrera-Martínez AD; Gahete MD; Pedraza-Arevalo S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Luque RM; Gálvez-Moreno MA; Castaño JP
Endocrine; 2018 Feb; 59(2):426-437. PubMed ID: 29196939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]